N30 Pharma Names Research VP

Boulder-based N30 Pharmaceuticals, the venture-backed developer of biopharmaceuticals for promoting human organ repair, regeneration and healing, said today that it has named Dr. Sherif Gabriel as vice President of Research. Gabriel was previously at the University of North Carolina Cystic Fibrosis Center, serving as Director of the Cystic Fibrosis Correction Core of the Center, and Associate Professor in the Department of Pediatrics, Division of Pulmonology. Gabriel's research has been focused on diseases such as cystic fibroses (CF) and and secretory diarrhea. CF is one of the company's first therapeutic targets, where it is in Phase 2a testing with its initial compound.